1. Home
  2. ENTO vs AUUD Comparison

ENTO vs AUUD Comparison

Compare ENTO & AUUD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • AUUD
  • Stock Information
  • Founded
  • ENTO 2014
  • AUUD 2012
  • Country
  • ENTO United States
  • AUUD United States
  • Employees
  • ENTO N/A
  • AUUD N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • AUUD Computer Software: Prepackaged Software
  • Sector
  • ENTO Health Care
  • AUUD Technology
  • Exchange
  • ENTO Nasdaq
  • AUUD Nasdaq
  • Market Cap
  • ENTO 2.3M
  • AUUD 2.6M
  • IPO Year
  • ENTO 2016
  • AUUD 2021
  • Fundamental
  • Price
  • ENTO $2.77
  • AUUD $2.18
  • Analyst Decision
  • ENTO
  • AUUD
  • Analyst Count
  • ENTO 0
  • AUUD 0
  • Target Price
  • ENTO N/A
  • AUUD N/A
  • AVG Volume (30 Days)
  • ENTO 5.3M
  • AUUD 4.6M
  • Earning Date
  • ENTO 08-14-2025
  • AUUD 08-08-2025
  • Dividend Yield
  • ENTO N/A
  • AUUD N/A
  • EPS Growth
  • ENTO N/A
  • AUUD N/A
  • EPS
  • ENTO N/A
  • AUUD N/A
  • Revenue
  • ENTO N/A
  • AUUD N/A
  • Revenue This Year
  • ENTO N/A
  • AUUD N/A
  • Revenue Next Year
  • ENTO N/A
  • AUUD N/A
  • P/E Ratio
  • ENTO N/A
  • AUUD N/A
  • Revenue Growth
  • ENTO N/A
  • AUUD N/A
  • 52 Week Low
  • ENTO $0.84
  • AUUD $2.12
  • 52 Week High
  • ENTO $2.95
  • AUUD $26.86
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 75.84
  • AUUD 34.79
  • Support Level
  • ENTO $1.73
  • AUUD $2.12
  • Resistance Level
  • ENTO $2.13
  • AUUD $2.64
  • Average True Range (ATR)
  • ENTO 0.30
  • AUUD 0.24
  • MACD
  • ENTO 0.08
  • AUUD 0.03
  • Stochastic Oscillator
  • ENTO 86.47
  • AUUD 6.19

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About AUUD Auddia Inc.

Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.

Share on Social Networks: